Valeant Pharmaceuticals: SEC Subpoena, Arizona Targets Company and Jorn Resigns

Valeant Pharmaceuticals: SEC Subpoena, Arizona Targets Company and Jorn Resigns by TheSkeptic If this week wasn’t bad enough for Valeant, Deb Jorn, the Executive Vice President and Company Group Chairman resigned today from the company. Ms. Jorn was responsible for all major US product launches as well as the Dermatology and GI therapeutic areas. These two areas were Valeant’s most important, representing HALF of Valeant’s forecasted 2016 US revenues. Moreover, Ms. Jorn was also responsible for the huge push of Dermatology products through the captive pharmacy channel they’d established with Philidor and it’s subsidiaries. Philidor is basically in a world…